Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | FADS1 | O60427 | 1/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | LTK | P29376 | 2/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.69 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.69 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393321 | 0.83 | AHR (0.97) | EGFRABCG2HTTFADS1AHR | |
| SCHEMBL5565226 | 0.83 | HTT (0.72) | EGFRABCG2HTTERBB2HIF1A | |
| SCHEMBL29058751 | 0.83 | EGFR (0.71) | EGFRABCG2HTTLCK | |
| SCHEMBL30395473 | 0.83 | EGFR (0.71) | EGFRABCG2HTTLCK | |
| SCHEMBL5569041 | 0.83 | EGFR (0.75) | EGFRABCG2HTTFADS1AHR | |
| SCHEMBL8920 | 0.82 | EGFR (1.00) | EGFRABCG2HTTFADS1AHR | |
| SCHEMBL29941271 | 0.82 | EGFR (1.00) | EGFRABCG2HTTFADS1AHR | |
| SCHEMBL2992623 | 0.82 | EGFR (1.00) | EGFRABCG2HTTFADS1AHR | |
| SCHEMBL4356660 | 0.82 | EGFR (1.00) | EGFRABCG2HTTFADS1AHR | |
| SCHEMBL5569900 | 0.82 | HTT (1.00) | EGFRABCG2HTTFADS1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010085747-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | ESRRA, ESRRB, NR5A1 | EGFR 768/4885ABCG2 2837/4885HTT 4357/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885ABCG2 311/4885HTT 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.